Leon Kircik, MD - What differentiates Siliq from other IL-17 biologics?

Leon Kircik, MD - What labs do you do before starting a biologic?Подробнее

Leon Kircik, MD - What are topical PDE-4 inhibitors being studied for?Подробнее

Leon Kircik, MD - Can you explain the different types of moisturizers for atopic dermatitis?Подробнее

Leon Kircik, MD - What other new molecules are being studied for Psoriasis?Подробнее

DecisionDx-Melanoma vs. Traditional Methods: Enhancing Melanoma Risk AssessmentПодробнее

lxekizumab Reduces key IL-17 and IL-23 Pathway Genes More Rapidly than Guselkumab | Lam Tsoi, PhDПодробнее

Brodalumab - Siliq - In a nutshell.Подробнее

Leon Kircik, MD - What dermatoses are topical JAK inhibitors being investigated for?Подробнее

Leon Kircik, MD - What would be a suitable treatment option for psoriasis patients on Medicare?Подробнее

Leon Kircik, MD - How does ruxolitinib cream fit in your treatment algorithm for your atopic derma..Подробнее

SiliqПодробнее

Leon Kircik, MD - Can you prescribe dupilumab to patients with a history of malignancy?Подробнее

Leon Kircik, MD - What are the contraindications to ruxolitinib cream?Подробнее

SLKПодробнее

Brodalumab mode of actionПодробнее

Leon Kircik, MD - How do you discuss ruxolitinib cream safety concerns with your patients?Подробнее

Leon Kircik, MD - In which patient populations should we be careful in prescribing ruxolitinib...Подробнее

Week 4 of Siliq! | November 2020 | Breaking the Puzzle | Weaver PresentationsПодробнее